Physician profile
Anthony J Dedea
NPI 1548600430
$3,640.84
in general payments reported to CMS, 2019-2025
25 companies · $266 in 2025
The $266 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $400 · 2020: $122 · 2021: $503 · 2022: $754 · 2023: $974 · 2024: $622 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,862.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,861.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $829.83 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $524.44 | 2021-2023 | Spravato, Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $294.11 | 2019-2023 | Jardiance |
| Abbvie INC. | $259.66 | 2021-2025 | Ubrelvy |
| Lilly USA, LLC | $227.90 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Pfizer INC. | $220.10 | 2021-2025 | |
| Amgen INC. | $167.40 | 2019-2025 | Otezla, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $167.22 | 2019-2024 | Airsupra, Breztri |
| Medtronic, INC. | $140.05 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $104.10 | 2022-2023 | |
| Idorsia Pharmaceuticals US INC | $94.53 | 2023-2024 | Quviviq |
| Glaxosmithkline, LLC. | $83.51 | 2022-2024 | Trelegy Ellipta |
| Abbott Laboratories | $76.28 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Exact Sciences Corporation | $54.50 | 2023-2025 | Cologuard Collection Kit |
| Organon LLC | $53.88 | 2022-2023 | Nexplanon |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Women'S Health, INC. | $53.60 | 2023 | Myrisk |
| Edwards Lifesciences Corporation | $49.82 | 2024 | Sapien 3 Ultra Resilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.66 | 2022-2024 | Xifaxan |
| Astellas Pharma US INC | $40.59 | 2024-2025 | Veozah |
| Abiomed | $37.63 | 2023 | Impella |
| Boston Scientific Corporation | $34.38 | 2023 | Watchman Flx |
| Cranial Technologies, INC | $31.08 | 2022-2024 | Doc Band |
| Dexcom, INC. | $22.00 | 2024 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $19.23 | 2024 | Korlym |
| Shield Therapeutics INC | $14.34 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Dedea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.